Split History
ETFs Holding ALBO »    ALBO Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Co.'s primary product candidate, odevixibat, is used for the indication of progressive familial intrahepatic cholestasis, a rare genetic disorder affecting young children. Co. is also developing odevixibat in biliary atresia and in Alagille syndrome. Co.'s other product candidate, elobixibat, is for the treatment of chronic constipation and for which Co. has a clinical trial as a treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. According to our ALBO split history records, Albireo Pharma has had 1 split.
ALBO split history picture
Albireo Pharma (ALBO) has 1 split in our ALBO split history database. The split for ALBO took place on November 04, 2016. This was a 1 for 30 reverse split, meaning for each 30 shares of ALBO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.

When a company such as Albireo Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ALBO split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Albireo Pharma shares, starting with a $10,000 purchase of ALBO, presented on a split-history-adjusted basis factoring in the complete ALBO split history. ALBO split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/29/2010
End date: 11/27/2020
Start price/share: $53.10
End price/share: $36.31
Dividends collected/share: $0.00
Total return: -31.62%
Average Annual Total Return: -3.73%
Starting investment: $10,000.00
Ending investment: $6,836.98
Years: 10.00
Date Ratio
11/04/20161 for 30
ALBO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ALC Split History
ALIM Split History
ALKS Split History
ALPN Split History
ALQA Split History
ALR Split History
ALT Split History
ALXA Split History
ALXN Split History
AMDA Split History

Also explore: ALBO shares outstanding history

Dolphin Entertainment, Inc. (DLPN)
HTG Molecular Diagnostics, Inc. (HTGM)
BIO-key International, Inc. (BKYI)
Cedar Realty Trust, Inc. (CDR)
Brookfield Renewable Partners L.P. (BEP)
Performance Shipping Inc. (PSHG)
Summit Midstream Partners, LP (SMLP)
Intec Pharma Ltd. (NTEC)
Duff & Phelps Select MLP and Midstream Energy Fund Inc. (DSE)
WidePoint Corporation (WYY)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ALBO Insider Buying

ALBO Split History | www.SplitHistory.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.